Neurotoxicity of Cancer Chemotherapy

Edward J Dropcho

doi:10.1055/s-0030-1255217

Seminars in Neurology, Table of Contents

Semin Neurol 2010; 30(3): 273-286
DOI: 10.1055/s-0030-1255217

Neurotoxicity of Cancer Chemotherapy

Edward J. Dropcho¹

¹Department of Neurology, Indiana University Medical Center, Indianapolis, Indiana

Abstract

ABSTRACT

Neurologic dysfunction is a common side effect of many chemotherapy drugs. For several agents, neurotoxicity is common, severe, and can be dose-limiting. As the list of newer chemotherapy agents and systemic “targeted therapies” grows, so does the number and variety of potential neurotoxicities. This is a review of the clinical features of chemotherapy-induced syndromes involving the central and peripheral nervous systems.

KEYWORDS

Chemotherapy adverse effects - polyneuropathy

Full Text

References

REFERENCES

1 Vassal G, Deroussent A, Hartmann O et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990; 50(19) 6203-6207
2 Wyllie A R, Bayliff C D, Kovacs M J. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother. 1997; 31(2) 171-174
3 Dropcho E J, Rosenfeld S S, Vitek J, Guthrie B L, Morawetz R B. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol. 1998; 36(2) 191-198
4 Baker W J, Royer Jr G L, Weiss R B. Cytarabine and neurologic toxicity. J Clin Oncol. 1991; 9(4) 679-693
5 Jaeckle K A, Batchelor T, O'Day S J et al.. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002; 57(3) 231-239
6 Jabbour E, O'Brien S, Kantarjian H et al.. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007; 109(8) 3214-3218
7 Leff R S, Thompson J M, Daly M B et al.. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer. 1988; 62(1) 32-35
8 Pratt C B, Green A A, Horowitz M E et al.. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol. 1986; 4(8) 1253-1261
9 Pratt C B, Goren M P, Meyer W H, Singh B, Dodge R K. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol. 1990; 8(8) 1399-1401
10 Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken J B. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000; 82(2) 291-294
11 Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs. 2004; 15(4) 347-350
12 Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007; 19 108-114
13 DiMaggio J R, Brown R, Baile W F, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer. 1994; 73(5) 1509-1514
14 Simonian N A, Gilliam F G, Chiappa K H. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology. 1993; 43(12) 2700-2702
15 Buesa J M, García-Teijido P, Losa R, Fra J. Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res. 2003; 9(12) 4636-4637
16 Pavol M A, Meyers C A, Rexer J L, Valentine A D, Mattis P J, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995; 45(5) 947-950
17 Valentine A D, Meyers C A, Kling M A, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25(1, Suppl 1) 39-47
18 Hensley M L, Peterson B, Silver R T, Larson R A, Schiffer C A, Szatrowski T P. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000; 18(6) 1301-1308
19 Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol. 1988; 6(4) 355-359
20 Meyers C A, Scheibel R S, Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology. 1991; 41(5) 672-676
21 Musselman D L, Lawson D H, Gumnick J F et al.. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13) 961-966
22 Denicoff K D, Rubinow D R, Papa M Z et al.. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987; 107(3) 293-300
23 Karp B I, Yang J C, Khorsand M, Wood R, Merigan T C. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology. 1996; 47(2) 417-424
24 Baz D V, Bofill J S, Nogueira J A. Irinotecan-induced dysarthria. J Natl Cancer Inst. 2001; 93(18) 1419-1420
25 Nieto Y, Cagnoni P J, Bearman S I et al.. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res. 1999; 5(3) 501-506
26 Perry J R, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996; 46(6) 1596-1599
27 Ziske C G, Schöttker B, Gorschlüter M et al.. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol. 2002; 13(4) 629-631
28 Rook J, Rosser T, Fangusaro J, Finlay J. Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatr Blood Cancer. 2008; 50(3) 699-700
29 Byrd R L, Rohrbaugh T M, Raney Jr R B, Norris D G. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer. 1981; 47(1) 37-40
30 Hurwitz R L, Mahoney Jr D H, Armstrong D L, Browder T M. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol. 1988; 16(3) 216-219
31 Jansen C E, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005; 104(10) 2222-2233
32 Kayl A E, Wefel J S, Meyers C A. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006; 13(4) 362-369
33 Vardy J, Rourke S, Tannock I F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007; 25(17) 2455-2463
34 Wefel J S, Lenzi R, Theriault R, Buzdar A U, Cruickshank S, Meyers C A. “Chemobrain” in breast carcinoma? A prologue. Cancer. 2004; 101(3) 466-475
35 Hermelink K, Untch M, Lux M P et al.. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007; 109(9) 1905-1913
36 Inagaki M, Yoshikawa E, Matsuoka Y et al.. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007; 109(1) 146-156
37 Silverman D H, Dy C J, Castellon S A et al.. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007; 103(3) 303-311
38 Ahles T A, Saykin A J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7(3) 192-201
39 Rosenblum M K, Delattre J Y, Walker R W, Shapiro W R. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol. 1989; 7(3) 269-281
40 Hook C C, Kimmel D W, Kvols L K et al.. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992; 31(3) 262-267
41 Savarese D M, Gordon J, Smith T W et al.. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis—a case report. Cancer. 1996; 77(2) 387-394
42 Franco D A, Greenberg H S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology. 2001; 56(1) 110-112
43 Takimoto C H, Lu Z H, Zhang R et al.. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996; 2(3) 477-481
44 Videnovic A, Semenov I, Chua-Adajar R et al.. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology. 2005; 65(11) 1792-1794 discussion 1685
45 Robain O, Dulac O, Dommergues J P et al.. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. J Neurol Neurosurg Psychiatry. 1984; 47(1) 65-72
46 Correa D D, DeAngelis L M, Shi W, Thaler H, Glass A, Abrey L E. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004; 62(4) 548-555
47 Harder H, Holtel H, Bromberg J E et al.. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004; 62(4) 544-547
48 Herrlinger U, Küker W, Uhl M Neuro-Oncology Working Group of the German Society et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005; 57(6) 843-847
49 Kingma A, van Dommelen R I, Mooyaart E L et al.. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr. 2001; 139 413-420
50 Montour-Proulx I, Kuehn S M, Keene D L et al.. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol. 2005; 20(2) 129-133
51 Reddick W E, Glass J O, Helton K J, Langston J W, Li C S, Pui C H. A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol. 2005; 26(9) 2371-2377
52 Omuro A M, Ben-Porat L S, Panageas K S et al.. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005; 62(10) 1595-1600
53 Oka M, Terae S, Kobayashi R et al.. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology. 2003; 45(7) 493-497
54 Rubinstein L J, Herman M M, Long T F, Wilbur J R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975; 35(2) 291-305
55 Lai R, Abrey L E, Rosenblum M K, DeAngelis L M. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004; 62(3) 451-456
56 Linnebank M, Moskau S, Jürgens A et al.. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro-oncol. 2009; 11(1) 2-8
57 Chun H G, Leyland-Jones B R, Caryk S M, Hoth D F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986; 70(10) 1225-1228
58 Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994; 12(10) 2216-2228
59 Cohen R B, Abdallah J M, Gray J R, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med. 1993; 118(2) 114-116
60 Feinberg W M, Swenson M R. Cerebrovascular complications of L-asparaginase therapy. Neurology. 1988; 38(1) 127-133
61 Mitchell L G, Andrew M, Hanna K Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA) et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003; 97(2) 508-516
62 Scappaticci F A, Skillings J R, Holden S N et al.. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99(16) 1232-1239
63 Zangari M, Fink L M, Elice F, Zhan F, Adcock D M, Tricot G J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009; 27(29) 4865-4873
64 Norden A D, Young G S, Setayesh K et al.. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70(10) 779-787
65 Narayana A, Kelly P, Golfinos J et al.. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009; 110(1) 173-180
66 Friedman H S, Prados M D, Wen P Y et al.. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28) 4733-4740
67 Nghiemphu P L, Green R M, Pope W B, Lai A, Cloughesy T F. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-oncol. 2008; 10(3) 355-360
68 Carden C P, Larkin J M, Rosenthal M A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro-oncol. 2008; 10(4) 624-630
69 El Amrani M, Heinzlef O, Debroucker T, Roullet E, Bousser M G, Amarenco P. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology. 1998; 51(3) 899-901
70 Serrano-Castro P J, Guardado-Santervás P, Olivares-Romero J. Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study. Eur Neurol. 2000; 44(1) 63-64
71 Russmann S, Winkler A, Lövblad K O, Stanga Z, Bassetti C. Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation. Eur Neurol. 2002; 48(3) 178-180
72 Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother. 2004; 38(2) 242-246
73 Bernard J T, Ameriso S, Kempf R A, Rosen P, Mitchell M S, Fisher M. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology. 1990; 40(1) 154-155
74 Walker R W, Allen J C, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol. 1986; 4(12) 1845-1850
75 Rubnitz J E, Relling M V, Harrison P L et al.. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia. 1998; 12(8) 1176-1181
76 Eichler A F, Batchelor T T, Henson J W. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-oncol. 2007; 9(3) 373-377
77 Inaba H, Khan R B, Laningham F H, Crews K R, Pui C H, Daw N C. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008; 19(1) 178-184
78 Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol. 2004; 25(10) 1688-1695
79 Fisher M J, Khademian Z P, Simon E M, Zimmerman R A, Bilaniuk L T. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol. 2005; 26(7) 1686-1689
80 Haykin M E, Gorman M, van Hoff J, Fulbright R K, Baehring J M. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol. 2006; 76 153-157
81 Balin J, Parmar H, Kujawski L. Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity. J Neurol Sci. 2008; 269(1-2) 169-171
82 Drachtman R A, Cole P D, Golden C B et al.. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002; 19(5) 319-327
83 Jaksic W, Veljkovic D, Pozza C, Lewis I. Methotrexate-induced leukoencephalopathy reversed by aminophylline and high-dose folinic acid. Acta Haematol. 2004; 111(4) 230-232
84 Ay H, Buonanno F S, Schaefer P W et al.. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998; 51(5) 1369-1376
85 Tam C S, Galanos J, Seymour J F, Pitman A G, Stark R J, Prince H M. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004; 77(1) 72-76
86 Sánchez-Carpintero R, Narbona J, López de Mesa R, Arbizu J, Sierrasesúmaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol. 2001; 24(2) 145-148
87 Suminoe A, Matsuzaki A, Kira R et al.. Reversible posterior leukoencephalopathy syndrome in children with cancers. J Pediatr Hematol Oncol. 2003; 25(3) 236-239
88 Morris E B, Laningham F H, Sandlund J T, Khan R B. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer. 2007; 48(2) 152-159
89 Shin R K, Stern J W, Janss A J, Hunter J V, Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology. 2001; 56(3) 388-391
90 Allen J A, Adlakha A, Bergethon P R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006; 63(10) 1475-1478
91 Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354(9) 980-982 discussion 980-982
92 Henderson R D, Rajah T, Nicol A J, Read S J. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology. 2003; 60(2) 326-328
93 Covarrubias D J, Luetmer P H, Campeau N G. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002; 23(6) 1038-1048
94 Smith G A, Damon L E, Rugo H S, Ries C A, Linker C A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997; 15(2) 833-839
95 Winkelman M D, Hines J D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol. 1983; 14(5) 520-527
96 Pirzada N A, Ali I I, Dafer R M. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000; 34(1) 35-38
97 Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol. 1997; 34(2) 163-167
98 Anderson N R, Tandon D S. Ifosfamide extrapyramidal neurotoxicity. Cancer. 1991; 68(1) 72-75
99 Resar L M, Phillips P C, Kastan M B, Leventhal B G, Bowman P W, Civin C I. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer. 1993; 71(1) 117-123
100 Raney B, Tefft M, Heyn R et al.. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer. 1992; 69(6) 1498-1506
101 McLean D R, Clink H M, Ernst P et al.. Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes. Cancer. 1994; 73(12) 3037-3040
102 Kleinschmidt-DeMasters B K, Yeh M. “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer. 1992; 70(10) 2504-2507
103 Richardson P G, Briemberg H, Jagannath S et al.. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006; 24(19) 3113-3120
104 Badros A, Goloubeva O, Dalal J S et al.. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007; 110(5) 1042-1049
105 Argyriou A A, Iconomou G, Kalofonos H P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008; 112(5) 1593-1599
106 San Miguel J F, Schlag R, Khuageva N K VISTA Trial Investigators et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9) 906-917
107 Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990; 66(6) 1117-1123
108 Cavaletti G, Marzorati L, Bogliun G et al.. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992; 69(1) 203-207
109 Ta L E, Espeset L, Podratz J, Windebank A J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006; 27(6) 992-1002
110 McWhinney S R, Goldberg R M, McLeod H L. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009; 8(1) 10-16
111 Dzagnidze A, Katsarava Z, Makhalova J et al.. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci. 2007; 27(35) 9451-9457
112 Boogerd W, ten Bokkel Huinink W W, Dalesio O, Hoppenbrouwers W J, van der Sande J J. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol. 1990; 9(3) 255-263
113 Strumberg D, Brügge S, Korn M W et al.. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002; 13(2) 229-236
114 Heinzlef O, Lotz J P, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998; 64(5) 667-669
115 Openshaw H, Slatkin N E, Stein A S, Hinton D R, Forman S J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer. 1996; 78(9) 1899-1905
116 Lee J J, Low J A, Croarkin E et al.. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol. 2006; 24(13) 2084-2091
117 Imrie K R, Couture F, Turner C C, Sutcliffe S B, Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant. 1994; 13(1) 77-79
118 Stein M E, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol. 1998; 21(3) 248-249
119 Saif M W, Wilson R H, Harold N, Keith B, Dougherty D S, Grem J L. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs. 2001; 12(6) 525-531
120 Saif M W, Wood T E, McGee P J, Diasio R B. Peripheral neuropathy associated with capecitabine. Anticancer Drugs. 2004; 15(8) 767-771
121 Frisk P, Stålberg E, Strömberg B, Jakobson A. Painful peripheral neuropathy after treatment with high-dose ifosfamide. Med Pediatr Oncol. 2001; 37(4) 379-382
122 Patel S R, Forman A D, Benjamin R S. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst. 1994; 86(4) 305-306
123 Koh S, Nelson Jr M D, Kovanlikaya A, Chen L S. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol. 1999; 21(2) 576-578
124 Bay A, Oner A F, Etlik O, Yilmaz C, Caksen H. Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol. 2005; 27(5) 270-272
125 Pascual A M, Coret F, Casanova B, Láinez M J. Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci. 2008; 267(1-2) 158-161
126 Argyriou A A, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos H P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008; 34(4) 368-377
127 Wilson R H, Lehky T, Thomas R R, Quinn M G, Floeter M K, Grem J L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20(7) 1767-1774
128 Lehky T J, Leonard G D, Wilson R H, Grem J L, Floeter M K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004; 29(3) 387-392
129 Webster R G, Brain K L, Wilson R H, Grem J L, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005; 146(7) 1027-1039
130 Krishnan A V, Goldstein D, Friedlander M, Kiernan M C. Oxaliplatin and axonal Na + channel function in vivo. Clin Cancer Res. 2006; 12(15) 4481-4484
131 Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002; 94(9) 2434-2440
132 Krishnan A V, Goldstein D, Friedlander M, Kiernan M C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005; 32(1) 51-60
133 Park S B, Lin C S, Krishnan A V, Goldstein D, Friedlander M L, Kiernan M C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009; 132(Pt 10) 2712-2723
134 Land S R, Kopec J A, Cecchini R S et al.. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25(16) 2205-2211
135 Durand J P, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs. 2005; 16(5) 587-591
136 Argyriou A A, Chroni E, Polychronopoulos P et al.. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006; 67(12) 2253-2255
137 Gamelin L, Boisdron-Celle M, Delva R et al.. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004; 10(12 Pt 1) 4055-4061
138 Gamelin L, Capitain O, Morel A et al.. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007; 13(21) 6359-6368
139 Chaudhry V, Eisenberger M A, Sinibaldi V J, Sheikh K, Griffin J W, Cornblath D R. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996; 119(Pt 6) 2039-2052
140 Soliven B, Dhand U K, Kobayashi K et al.. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve. 1997; 20(1) 83-91
141 Cavaletti G, Bogliun G, Marzorati L et al.. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995; 75(5) 1141-1150
142 Forsyth P A, Balmaceda C, Peterson K, Seidman A D, Brasher P, DeAngelis L M. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997; 35(1) 47-53
143 Hilkens P H, Verweij J, Stoter G, Vecht C J, van Putten W L, van den Bent M J. Peripheral neurotoxicity induced by docetaxel. Neurology. 1996; 46(1) 104-108
144 New P Z, Jackson C E, Rinaldi D, Burris H, Barohn R J. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology. 1996; 46(1) 108-111
145 Persohn E, Canta A, Schoepfer S et al.. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005; 41(10) 1460-1466
146 Lee J J, Swain S M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006; 24(10) 1633-1642
147 Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006; 42(1) 24-30
148 van den Bent M J, Hilkens P H, Sillevis Smitt P A, van Raaij-van den Aarssen V J, Bontenbal M, Verweij J. Lhermitte's sign following chemotherapy with docetaxel. Neurology. 1998; 50(2) 563-564
149 Chaudhry V, Rowinsky E K, Sartorius S E, Donehower R C, Cornblath D R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994; 35(3) 304-311
150 Freilich R J, Balmaceda C, Seidman A D, Rubin M, DeAngelis L M. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996; 47(1) 115-118
151 Chaudhry V, Chaudhry M, Crawford T O, Simmons-O'Brien E, Griffin J W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003; 60(2) 337-340
152 Berger T, Malayeri R, Doppelbauer A et al.. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer. 1997; 33(9) 1393-1399
153 Cavaletti G, Beronio A, Reni L et al.. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology. 2004; 62(12) 2291-2293
154 Molloy F M, Floeter M K, Syed N A et al.. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001; 24(8) 1050-1057
155 Chaudhry V, Cornblath D R, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002; 59(12) 1872-1875
156 Tosi P, Zamagni E, Cellini C et al.. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005; 74(3) 212-216
157 Offidani M, Corvatta L, Marconi M et al.. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol. 2004; 72(6) 403-409
158 Mileshkin L, Stark R, Day B, Seymour J F, Zeldis J B, Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006; 24(27) 4507-4514
159 Plasmati R, Pastorelli F, Cavo M et al.. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007; 69(6) 573-581
160 Casey E B, Jellife A M, Le Quesne P M, Millett Y L. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973; 96(1) 69-86
161 Verstappen C C, Koeppen S, Heimans J J et al.. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005; 64(6) 1076-1077
162 Graf W D, Chance P F, Lensch M W, Eng L J, Lipe H P, Bird T D. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996; 77(7) 1356-1362
163 Hildebrandt G, Holler E, Woenkhaus M et al.. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol. 2000; 11(6) 743-747
164 Kalfakis N, Panas M, Karadima G, Floroskufi P, Kokolakis N, Vassilopoulos D. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology. 2002; 59(9) 1470-1471
165 Weintraub M, Adde M A, Venzon D J et al.. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol. 1996; 14(3) 935-940
166 Pace A, Bove L, Nisticò C et al.. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry. 1996; 61(4) 409-411
167 Apfel S C. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest. 2000; 18(6) 564-573
168 Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer. 2002; 38(14) 1832-1837
169 Leong S S, Tan E H, Fong K W et al.. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2003; 21(9) 1767-1774
170 Lorusso D, Ferrandina G, Greggi S Multicenter Italian Trials in Ovarian Cancer invesitgators et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003; 14(7) 1086-1093
171 Openshaw H, Beamon K, Synold T W et al.. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res. 2004; 10(2) 461-467
172 De Vos F Y, Bos A M, Schaapveld M et al.. A randomized phase II study of paclitaxel with carboplatin + /- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol. 2005; 97(1) 60-67
173 Hensley M L, Hagerty K L, Kewalramani T et al.. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009; 27(1) 127-145
174 Cascinu S, Catalano V, Cordella L et al.. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002; 20(16) 3478-3483
175 Argyriou A A, Chroni E, Koutras A et al.. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005; 64(1) 26-31
176 Bianchi G, Vitali G, Caraceni A et al.. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005; 41(12) 1746-1750
177 Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005; 91(2) 135-138

Edward J DropchoM.D.

Department of Neurology, Indiana University Medical Center

CL 292, Indianapolis, Indiana 46202

Email: edropcho@iupui.edu